60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is a Washington, D.C.-based specialty pharmaceutical company developing and commercializing treatments for vector-borne infectious diseases. Its lead commercial asset is ARAKODA® (tafenoquine), the only FDA-approved, broad-spectrum, once-weekly malaria prevention drug on the U.S. market, co-developed with the U.S. Army and commercially available since 2019. H.C. Wainwright analyst Matthew Keller reiterated a Buy rating and $24.00 price target on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) on February 2, 2026, while Ascendiant Capital Markets maintains a Buy rating and $11.20 price target, producing a median analyst price target of $17.60 against a recent share price of $1.71, which implies upside of roughly 929% to the median and up to 1,304% to the high target. The most recent catalyst came on April 15, 2026, when the company announced that ARAKODA is now live for purchase on the Runway Health travel medicine website, activating a new direct-to-consumer channel for U.S. international travelers.
| Recent Price | $1.435 |
| Market Cap | $3.78M |
| 52-Week Range | $1.29 - $12.24 |
| Shares Outstanding | 2.66M |
| Volume | 17,780 |
(Source: Stock Analysis)
What 60 Degrees Pharmaceuticals (Nasdaq: SXTP) Actually Does
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is primarily built around a single active pharmaceutical ingredient: tafenoquine. Originally discovered by the Walter Reed Army Institute of Research and licensed through a partnership with the U.S. Army Medical Materiel Development Activity, tafenoquine has a half-life of approximately 16 days, allowing for once-weekly dosing. That profile sets ARAKODA apart from daily antimalarials and makes it a more convenient option for international travelers.
(Source: 60 Degrees Pharmaceuticals, Inc.)
Beyond malaria, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is running three clinical programs evaluating tafenoquine as a treatment for babesiosis, a tick-borne infection caused by the Babesia parasite that currently has no FDA-approved treatment. The company is also advancing Australian Chestnut Extract as a non-prescription dietary supplement, having filed a New Dietary Ingredient Notification with the FDA in March 2026, with an FDA decision deadline of May 25, 2026.
The Market Backdrop: Ticks, Travelers, and an Unmet Need
Two structural tailwinds drive the long-term thesis for 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP): rising demand for travel medicine and a rapid increase in tick-borne disease in the United States.
(Source: Mordor Intelligence)
On the malaria side, the World Health Organization's 2025 World Malaria Report documented 282 million cases and 610,000 deaths globally in 2024, an increase of roughly 9 million cases year-over-year. The same report highlights that partial resistance to artemisinin, the current backbone of malaria treatment, has now been confirmed or suspected in at least eight African countries. That resistance trend reinforces demand for mechanistically differentiated prophylactics such as ARAKODA.
On the tick-borne disease front, a Penn State College of Medicine study published in Open Forum Infectious Diseases found that babesiosis cases in the United States increased by an average of 9% per year between 2015 and 2022, with roughly 4 in 10 patients coinfected with another tick-borne illness. The CDC notes that the disease is spreading into new geographic areas as tick populations expand and that cases are likely underreported because symptoms mimic those of influenza and Lyme disease. There is still no FDA-approved drug treatment for babesiosis.
ARAKODA's Edge and the Commercial Build-Out
ARAKODA is the only FDA-approved antimalarial providing broad-spectrum coverage across every life-cycle stage of the malaria parasite in a once-weekly oral tablet. Its safety profile has been validated across eight published clinical studies involving more than 1,100 patients, with adverse event rates comparable to placebo at the approved dose. Distribution infrastructure is already established through major national wholesalers and retail pharmacies, giving the company an operational head start as it scales.
The commercial push accelerated sharply in the first four months of 2026. In January, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) announced a partnership with Runway Health, a direct-to-patient telehealth platform that connects travelers with licensed physicians for pre-departure prescriptions. In February, the company launched a GoodRx partnership expanding ARAKODA access to more than 70,000 pharmacies with patient savings of up to 30%. On April 15, 2026, the company confirmed that ARAKODA is now live and available for purchase on the Runway Health website, allowing U.S. travelers to complete an online consultation and receive the medication at home before departure. The announcement activated a channel that aligns ARAKODA with the exact decision moment when a traveler is booking a trip to a malaria-endemic region.
The commercial momentum is flowing through to the financials. According to the company's March 31, 2026 earnings release, fiscal year 2025 results include:
- Net product revenues increased 65% year-over-year to approximately $1.0 million
- Operating expenses fell to $8.4 million from $10.0 million in 2024
- Net loss improved to approximately $7.4 million from $8.0 million in the prior year
In addition, Q3 2025 product revenue surged 223% year-over-year to $438,000, the highest quarterly volume to date.
Babesiosis: A Clinical Program That Could Define the Company
The most important catalyst for 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is the babesiosis program. On March 11, 2026, the company announced that all three patients enrolled in its expanded access trial for relapsing babesiosis in immunosuppressed patients were cured following the tafenoquine regimen. Cure was confirmed using an FDA-licensed RNA amplification assay described as at least 100 times more sensitive than a standard blood smear. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) called for a review of existing treatment guidelines based on the result.
(Source: 60 Degrees Pharmaceuticals, Inc.)
The company is running three simultaneous babesiosis clinical programs. The randomized hospital-based Phase 2 study could yield an interim analysis as early as late September 2026 if 2026 tick-season enrollment mirrors last year's patterns. The B-FREE Chronic Babesiosis Study, now enrolling at the Icahn School of Medicine at Mount Sinai, is a 12-month open-label trial evaluating a 90-day tafenoquine regimen for patients with chronic babesiosis and persistent fatigue.
Management estimates the U.S. babesiosis market at up to 380,000 addressable patients annually, representing up to $245 million in potential peak annual sales and up to $1.1 billion in cumulative revenue through patent expiration in 2035.
How the Analysts Arrived at Their Price Targets
H.C. Wainwright analyst Matthew Keller's $24.00 price target for 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is built on a clinical net present value model focused on tafenoquine for babesiosis in the United States, using a 100% contribution weight and an 18% probability of success. Because of limited current revenue visibility, the model does not yet assign value to ARAKODA malaria sales, which the analyst flags as a source of potential upside. Ascendiant Capital Markets analyst Lucas Ward values the company at $11.20 using a net present value approach that probability-weights cash flows from both ARAKODA and the babesiosis program. Both analysts hold Buy ratings, placing the median consensus target at $17.60.
Risks
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has disclosed substantial doubt about its ability to continue as a going concern. The company exhausted its current at-the-market facility capacity after raising approximately $4.0 million through March 2026 and will need additional capital to fund operations and clinical programs. The babesiosis program remains in Phase 2, positive expanded access data do not guarantee success in a randomized setting, and trial enrollment depends on seasonal tick activity.
The Investment Argument
At a market capitalization of under $5 million, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) trades at a level that appears to assign little value to ARAKODA's commercial trajectory and essentially no value to the babesiosis opportunity. The company has delivered a 100% cure rate in an expanded access trial for a disease with no approved treatment, grown product revenue 65% in fiscal year 2025, filed a dietary ingredient notification with an FDA decision due May 25, 2026, and brought ARAKODA live on a consumer-facing travel medicine platform reaching international travelers at the point of trip planning.
Babesiosis incidence is rising 9% per year, its geographic range continues to expand, and no FDA-approved treatment exists. With clinical partnerships at Yale, Tufts, Rhode Island Hospital, Mount Sinai, and Tulane, a randomized Phase 2 interim readout possible as early as late September 2026, and analyst price targets of $11.20 and $24.00 bracketing a median of $17.60, the setup heading into the back half of 2026 is shaping up around a sequence of catalysts that the current share price does not appear to reflect.
Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Sixty Degrees Pharma (SXTP) is a client of RedChip Companies. SXTP agreed to pay RedChip Companies, Inc. a $9,500 monthly cash fee, beginning in March 2023, and $40,000 of Rule 144 stock (based on the 30-day average price after the IPO) for six months of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. SXTP also agreed to pay RedChip a one-time $70,000 fee for a national TV ad campaign aired weekdays from May 20 to June 7, 2024, and a $55,000 fee for a national TV ad campaign aired weekdays from July 28 to August 7, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.